Thomas Piper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5966732/publications.pdf

Version: 2024-02-01

64 1,416 23 34 papers citations h-index g-index

64 64 64 781 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Investigations in carbon isotope ratios of seized testosterone and boldenone preparations. Drug Testing and Analysis, 2022, 14, 514-518.	2.6	6
2	Urinary phenylethylamine metabolites as potential markers for sports drug testing purposes. Biomedical Chromatography, 2022, 36, e5274.	1.7	4
3	Investigations on the <i>in vivo</i> metabolism of 5αâ€androstâ€2â€enâ€17â€one. Rapid Communications in M Spectrometry, 2022, 36, .	lass 1.5	2
4	An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. Drug Testing and Analysis, 2021, 13, 916-928.	2.6	8
5	Current Insights into the Steroidal Module of the Athlete Biological Passport. International Journal of Sports Medicine, 2021, 42, 863-878.	1.7	14
6	Carbon isotope ratios of endogenous steroids found in human serum—method development, validation, and reference population-derived thresholds. Analytical and Bioanalytical Chemistry, 2021, 413, 5655-5667.	3.7	9
7	Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114312.	2.8	15
8	Sensitive detection of testosterone and testosterone prohormone administrations based on urinary concentrations and carbon isotope ratios of androsterone and etiocholanolone. Drug Testing and Analysis, 2021, 13, 1835-1851.	2.6	4
9	Androgens, sports, and detection strategies for anabolic drug use. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, , 101609.	4.7	6
10	Identification of Trenbolone Metabolites Using Hydrogen Isotope Ratio Mass Spectrometry and Liquid Chromatography/High Accuracy/High Resolution Mass Spectrometry for Doping Control Analysis. Frontiers in Chemistry, 2020, 8, 435.	3.6	11
11	Detecting the misuse of 7â€oxoâ€DHEA by means of carbon isotope ratio mass spectrometry in doping control analysis. Rapid Communications in Mass Spectrometry, 2020, 34, e8776.	1.5	8
12	Implementation and Performance of the Gas Chromatography/Combustion/Isotope Ratio Mass Spectrometry-Based Method for the Confirmatory Analysis of Endogenous Anabolic Steroids during the Rio de Janeiro Olympic and Paralympic Games 2016. Analytical Chemistry, 2019, 91, 11747-11756.	6.5	6
13	Safety, hemodynamic effects, and detection of acute xenon inhalation: rationale for banning xenon from sport. Journal of Applied Physiology, 2019, 127, 1511-1518.	2.5	7
14	Effect of acute and chronic xenon inhalation on erythropoietin, hematological parameters, and athletic performance. Journal of Applied Physiology, 2019, 127, 1503-1510.	2.5	9
15	Analysis of endogenous steroids in urine by means of multi-immunoaffinity chromatography and isotope ratio mass spectrometry for sports drug testing. Analytical and Bioanalytical Chemistry, 2019, 411, 7563-7571.	3.7	4
16	Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. Drug Testing and Analysis, 2019, 11, 1644-1655.	2.6	16
17	Studies on thein vivometabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. Drug Testing and Analysis, 2018, 10, 1646-1656.	2.6	17
18	Case Study: Atypical <i>δ</i> ¹³ C values of urinary norandrosterone. Drug Testing and Analysis, 2018, 10, 1728-1733.	2.6	9

#	Article	IF	Citations
19	Development and validation of a multidimensional gas chromatography/combustion/isotope ratio mass spectrometry-based test method for analyzing urinary steroids in doping controls. Analytica Chimica Acta, 2018, 1030, 105-114.	5.4	17
20	Xenon elimination kinetics following brief exposure. Drug Testing and Analysis, 2017, 9, 666-670.	2.6	9
21	GHB-O- $\hat{1}^2$ -glucuronide in blood and urine is not a suitable tool for the extension of the detection window after GHB intake. Forensic Toxicology, 2017, 35, 263-274.	2.4	18
22	Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YKâ€11 for doping control purposes. Rapid Communications in Mass Spectrometry, 2017, 31, 1175-1183.	1.5	19
23	Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots. Clinical Mass Spectrometry, 2017, 6, 13-20.	1.9	7
24	Epiandrosterone sulfate prolongs the detectability of testosterone, 4â€androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. Drug Testing and Analysis, 2017, 9, 1695-1703.	2.6	41
25	Carbon isotope ratios of endogenous steroids in Belgian Blue and Holstein cattle: Method development, reference population studies and application to steroid misuse control. Rapid Communications in Mass Spectrometry, 2017, 31, 1793-1802.	1.5	2
26	Potential of GHB phase-II-metabolites to complement current approaches in GHB post administration detection. Forensic Science International, 2017, 279, 157-164.	2.2	23
27	Development and validation of a HPLC–QTOF-MS method for the determination of GHB-β-O-glucuronide and GHB-4-sulfate in plasma and urine. Forensic Toxicology, 2017, 35, 77-85.	2.4	9
28	Applications of Isotope Ratio Mass Spectrometry in Sports Drug Testing Accounting for Isotope Fractionation in Analysis of Biological Samples. Methods in Enzymology, 2017, 596, 403-432.	1.0	18
29	Genotypeâ€dependent metabolism of exogenous testosterone – new biomarkers result in prolonged detectability. Drug Testing and Analysis, 2016, 8, 1163-1173.	2.6	33
30	Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 6431-6442.	3.7	2
31	Optimization of an online heartâ€cutting multidimensional gas chromatography cleanâ€up step for isotopic ratio mass spectrometry and simultaneous quadrupole mass spectrometry measurements of endogenous anabolic steroid in urine. Drug Testing and Analysis, 2016, 8, 1204-1211.	2.6	22
32	Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing. Journal of Pharmaceutical and Biomedical Analysis, 2016, 123, 132-140.	2.8	39
33	Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2016, 162, 80-91.	2.5	20
34	Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls. Drug Testing and Analysis, 2015, 7, 1057-1062.	2.6	9
35	Urine analysis concerning xenon for doping control purposes. Rapid Communications in Mass Spectrometry, 2015, 29, 61-66.	1.5	15
36	Determination of ¹³ C/ ¹² C ratios of endogenous urinary 5â€aminoâ€imidazoleâ€4â€carboxamide 1βâ€Dâ€ribofuranoside (AICAR). Rapid Communications in Mass Spec 2014, 28, 1194-1202.	tromsetry,	22

#	Article	IF	Citations
37	Measuring xenon in human plasma and blood by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 1501-1506.	1.5	25
38	Quantifying cobalt in doping control urine samples – a pilot study. Drug Testing and Analysis, 2014, 6, 1186-1190.	2.6	26
39	Carbon Isotope Ratio Analysis of Steroids by High-Temperature Liquid Chromatography-Isotope Ratio Mass Spectrometry. Analytical Chemistry, 2014, 86, 2297-2302.	6.5	14
40	Identification of black market products and potential doping agents in Germany 2010–2013. European Journal of Clinical Pharmacology, 2014, 70, 1303-1311.	1.9	84
41	Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of <i>in vivo</i> Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control Purposes. European Journal of Mass Spectrometry, 2014, 20, 73-83.	1.0	16
42	Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. Analytical and Bioanalytical Chemistry, 2013, 405, 9703-9709.	3.7	19
43	Hydrogen isotope ratio mass spectrometry and highâ€resolution/highâ€accuracy mass spectrometry in metabolite identification studies: Detecting target compounds for sports drug testing. Rapid Communications in Mass Spectrometry, 2013, 27, 1904-1912.	1.5	25
44	Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 5455-5466.	3.7	36
45	Effect of changes in the deuterium content of drinking water on the hydrogen isotope ratio of urinary steroids in the context of sports drug testing. Analytical and Bioanalytical Chemistry, 2013, 405, 2911-2921.	3.7	2
46	Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACPâ€105. Rapid Communications in Mass Spectrometry, 2013, 27, 1173-1182.	1.5	20
47	Investigations on hydrogen isotope ratios of endogenous urinary steroids: referenceâ€populationâ€based thresholds and proofâ€ofâ€concept. Drug Testing and Analysis, 2012, 4, 717-727.	2.6	32
48	Influences of \hat{I}^2 -HCG administration on carbon isotope ratios of endogenous urinary steroids. Steroids, 2012, 77, 644-654.	1.8	6
49	Investigations on carbon isotope ratios and concentrations of urinary formestane. Drug Testing and Analysis, 2012, 4, 942-950.	2.6	22
50	Investigations on changes in $\langle \sup 13 \langle \sup > C \rangle 12 \langle \sup > C \rangle$ ratios of endogenous urinary steroids after pregnenolone administration. Drug Testing and Analysis, 2011, 3, 283-290.	2.6	13
51	Recent developments in the use of isotope ratio mass spectrometry in sports drug testing. Analytical and Bioanalytical Chemistry, 2011, 401, 433-447.	3.7	66
52	Determination of ¹³ C/ ¹² C ratios of urinary excreted boldenone and its main metabolite 5βâ€androstâ€1â€enâ€17βâ€olâ€3â€one. Drug Testing and Analysis, 2010, 2, 217-224.	2.6	29
53	Degradation of urine samples and its influence on the ¹³ C/ ¹² C ratios of excreted steroids. Drug Testing and Analysis, 2010, 2, 620-629.	2.6	23
54	Reporting and managing elevated testosterone/epitestosterone ratios-Novel aspects after five years' experience. Drug Testing and Analysis, 2010, 2, 637-642.	2.6	26

#	Article	IF	CITATION
55	Determination of sup 13 /sup C/sup 12 /sup C ratios of endogenous urinary steroids excreted as sulpho conjugates. Rapid Communications in Mass Spectrometry, 2010, 24, 3171-3181.	1.5	46
56	Metabolism of androstaâ€1,4,6â€trieneâ€3,17â€dione and detection by gas chromatography/mass spectrometry in doping control. Rapid Communications in Mass Spectrometry, 2009, 23, 207-218.	1.5	29
57	Determination of the deuterium/hydrogen ratio of endogenous urinary steroids for doping control purposes. Rapid Communications in Mass Spectrometry, 2009, 23, 1917-1926.	1.5	31
58	¹³ C/ ¹² C Ratios of endogenous urinary steroids investigated for doping control purposes. Drug Testing and Analysis, 2009, 1, 65-72.	2.6	36
59	Determination of ¹³ C/ ¹² C ratios of urinary epitestosterone and its main metabolites 5α―and 5β―androstaneâ€3α, 17Ĭ±â€diol. Drug Testing and Analysis, 2009, 1, 576-586.	2.6	32
60	6αâ€Methylandrostenedione: gas chromatographic mass spectrometric detection in doping control. Rapid Communications in Mass Spectrometry, 2008, 22, 321-329.	1.5	20
61	Determination of ¹³ C/ ¹² C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Communications in Mass Spectrometry, 2008, 22, 2161-2175.	1.5	151
62	Detection of Dehydroepiandrosterone Misuse by Means of Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry. European Journal of Mass Spectrometry, 2007, 13, 419-426.	1.0	27
63	Improved Performance and Maintenance in Gas Chromatography/Isotope Ratio Mass Spectrometry by Precolumn Solvent Removal. Analytical Chemistry, 2007, 79, 4162-4168.	6.5	27
64	Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. Analyst. The. 2006. 131, 1021-1026.	3.5	53